9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine has been researched along with EHS Tumor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balzarini, J; De Clercq, E; Holy, A; Naesens, L; Neyts, J; Rosenberg, I | 1 |
| Balzarini, J; De Clercq, E; Naesens, L | 1 |
2 other study(ies) available for 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine and EHS Tumor
| Article | Year |
|---|---|
Efficacy of oral 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice.
Topics: Adenine; Administration, Oral; Animals; Antiviral Agents; Cytomegalovirus Infections; Friend murine leukemia virus; Injections, Intraperitoneal; Leukemia, Experimental; Mice; Moloney murine sarcoma virus; Sarcoma, Experimental; Survival Rate; Treatment Outcome | 1993 |
Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo.
Topics: Adenine; Animals; Animals, Newborn; Antiviral Agents; Cell Line; Cell Transformation, Viral; Drug Administration Schedule; Injections, Intraperitoneal; Mice; Moloney murine sarcoma virus; Organophosphonates; Sarcoma, Experimental | 1991 |